Citigroup’s Alpine Immune Sciences Inc ALPN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q2 | – | Sell |
-207,496
| Closed | -$8.23M | – | 5848 |
|
|
2024
Q1 | $8.23M | Buy |
207,496
+171,719
| +480% | +$5.07M | 0.01% | 1367 |
|
|
2023
Q4 | $682K | Buy |
35,777
+35,107
| +5,240% | +$488K | ﹤0.01% | 3163 |
|
|
2023
Q3 | $7.67K | Sell |
670
-9,606
| -93% | -$118K | ﹤0.01% | 4611 |
|
|
2023
Q2 | $106K | Buy |
10,276
+9,753
| +1,865% | +$87.9K | ﹤0.01% | 4224 |
|
|
2023
Q1 | $4.04K | Sell |
523
-71
| -12% | -$566 | ﹤0.01% | 4987 |
|
|
2022
Q4 | $4.37K | Sell |
594
-25
| -4% | -$160 | ﹤0.01% | 5065 |
|
|
2022
Q3 | $4K | Sell |
619
-978
| -61% | -$8.06K | ﹤0.01% | 5341 |
|
|
2022
Q2 | $14K | Buy |
1,597
+554
| +53% | +$4.78K | ﹤0.01% | 5210 |
|
|
2022
Q1 | $9K | Sell |
1,043
-2,723
| -72% | -$23.5K | ﹤0.01% | 5605 |
|
|
2021
Q4 | $52K | Buy |
3,766
+2,440
| +184% | +$30.2K | ﹤0.01% | 5046 |
|
|
2021
Q3 | $14K | Buy |
1,326
+774
| +140% | +$7.13K | ﹤0.01% | 5391 |
|
|
2021
Q2 | $5K | Sell |
552
-5,364
| -91% | -$58.3K | ﹤0.01% | 5859 |
|
|
2021
Q1 | $63K | Sell |
5,916
-2,980
| -33% | -$37.2K | ﹤0.01% | 4589 |
|
|
2020
Q4 | $112K | Buy |
+8,896
| New | +$87.3K | ﹤0.01% | 5451 |
|
|
2016
Q2 | – | Sell |
-1,046
| Closed | -$18K | – | 7513 |
|
|
2016
Q1 | $18K | Buy |
1,046
+1,041
| +20,820% | +$20.8K | ﹤0.01% | 6599 |
|
|
2015
Q4 | $0 | Buy |
5
+4
| +400% | +$137 | ﹤0.01% | 7927 |
|
|
2015
Q3 | $0 | Buy |
+1
| New | +$66 | ﹤0.01% | 7784 |
|
Citigroup's ALPN Position: Q2 2024 in Review
Citigroup sold out of Alpine Immune Sciences Inc (ALPN) in Q2 2024, closing a stake of 207,496 shares — an estimated $8.23M sold.
Citigroup first reported a position in ALPN in Q3 2015 and held it in 17 quarters. The position peaked at $8.23M in Q1 2024. 0 funds tracked by Wall St. Rank hold ALPN as of Q2 2024.
- Citigroup reported no remaining Alpine Immune Sciences Inc position as of Q2 2024 after selling out during the quarter.
- Citigroup sold 207,496 Alpine Immune Sciences Inc shares in Q2 2024, an estimated $8.23M.
- Citigroup first reported a position in Alpine Immune Sciences Inc in Q3 2015 and held it in 17 quarters.
- Citigroup's Alpine Immune Sciences Inc position peaked at $8.23M in Q1 2024.
- 0 funds tracked by Wall St. Rank held Alpine Immune Sciences Inc as of Q2 2024.
Based on Citigroup's 13F filing for Q2 2024, filed 12 Aug 2024.